Video: FDA Alert: Dupixent Linked to Skin Cancer (CTCL) | Know Your Legal Rights
August 28, 2025
Transcript
Dupixent and Cutaneous T-Cell Lymphoma: What You Must Know
Have you or someone you love been prescribed Dupixent for eczema or atopic dermatitis, and were later diagnosed with a rare skin cancer called cutaneous T-cell lymphoma (CTCL)?
I’m Attorney Tracy Paulsen with Rightful Legal, and this is information you need to hear.
FDA Safety Alert Issued – March 31, 2025
On March 31, 2025, the FDA issued a safety alert after identifying a possible connection between Dupixent (dupilumab) and cutaneous T-cell lymphoma.
This is serious, and you deserve the facts—about your health, and about your legal rights.
What Is Eczema and Why Is Dupixent Prescribed?
Eczema, also known as atopic dermatitis, is a chronic skin condition that causes:
- Red, itchy, inflamed patches
- Cracked or bleeding skin
- Increased risk of infection
It’s not just dry skin—it’s caused by an overactive immune system that disrupts the skin’s protective barrier. When standard treatments fail, doctors may prescribe medications like Dupixent.
Approved by the FDA in 2017, Dupixent is used to treat moderate to severe eczema. It works by blocking two immune system proteins—interleukin-4 and interleukin-13—that cause inflammation.
While many patients report relief, altering the immune system may also change how the body detects and controls cancerous cells.
What Is Cutaneous T-Cell Lymphoma (CTCL)?
CTCL is a rare form of non-Hodgkin lymphoma that begins in T-lymphocytes (white blood cells) in the skin. Unlike other lymphomas that begin in lymph nodes, CTCL starts in the skin and can spread to:
- Lymph nodes
- Bloodstream
- Internal organs
The two most common types are:
- Mycosis fungoides – a slower-growing form often mistaken for eczema or psoriasis.
- Sézary syndrome – a more aggressive form where cancerous T-cells are found in both the skin and blood.
Symptoms may include:
- Red, scaly patches
- Severe itching
- Skin tumors
- Enlarged lymph nodes
Why CTCL Is Often Misdiagnosed as Eczema
CTCL can look exactly like eczema in its early stages. As a result, many patients may:
- Be misdiagnosed
- Begin Dupixent treatment
- And unknowingly worsen or accelerate cancer symptoms
FDA Findings on Dupixent and Cancer Risks
By late 2024, the FDA had reviewed its Adverse Event Reporting System (FAERS) and found enough cases to issue a new safety signal in March 2025.
The concern is twofold:
- New CTCL diagnoses that appear after starting Dupixent.
- Unmasking of previously undiagnosed CTCL, with Dupixent accelerating its progression.
Drug Companies Failed to Warn the Public
Despite this evidence, Dupixent’s label contains no warning about CTCL. Sanofi and Regeneron—the drug’s manufacturers—have:
- Promoted the drug widely
- Failed to require pre-treatment cancer screenings
- Not updated their label to warn patients or doctors
As a result, many patients started treatment unaware of these risks.
Who May Qualify for a Dupixent Lawsuit?
Rightful Legal is now investigating claims nationwide for individuals who:
- Took Dupixent for eczema or atopic dermatitis, and
- Were diagnosed with CTCL afterward,
- Had no prior lymphoma diagnosis, or
- Experienced rapid progression of undiagnosed CTCL
- Were never warned about this potential risk
If this describes you or a loved one, you may be entitled to financial compensation through a legal claim.
Time Is Limited – Know Your Statute of Limitations
The statute of limitations to file a lawsuit differs from state to state. The clock may already be ticking on your right to bring a claim.
While the FDA continues reviewing data, Sanofi and Regeneron still haven’t updated Dupixent’s warning label.
Don’t wait.
Contact Rightful Legal for a Free Case Review
If you or someone you love took Dupixent and was later diagnosed with cutaneous T-cell lymphoma, you can contact me directly.
📞 Call 617-821-5856
🌐 Visit RightfulLegal.com to schedule a free, confidential consultation.
We are here to review your case, explain your rights, and fight for the justice you deserve.